SCHEMBL1786995

SCHEMBL1786995

CC(=O)c1c(-c2cccc(Br)c2)nc2ccccn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.55
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.49
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MARK4 Q96L34 4/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NTRK1 P04629 1/20 0.44
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43
▸ TUBA3C P0DPH7 1/20 0.43
▸ TUBA1B P68363 1/20 0.43
▸ TUBA4A P68366 1/20 0.43
▸ TUBB4B P68371 1/20 0.43
▸ TUBB3 Q13509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579818 0.86 CYP1A2 (0.54) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL1788950 0.85 SMN1; SMN2 (0.49) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL13312213 0.85 CYP1A2 (0.67) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL12651708 0.84 SMN1; SMN2 (0.48) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL12651563 0.82 KMT2A (0.52) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL1791855 0.81 ALDH1A1 (0.67) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL12651709 0.80 ALDH1A1 (0.46) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL21712552 0.77 ALDH1A1 (0.67) KMT2ACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL24122954 0.77 NPC1 (0.48) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL23509651 0.77 AKT2 (0.51) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 — — US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 — — EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 KMT2A 2567/4885CYP1A2 4754/4885CYP2C9 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback